<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Biomedical Science1021-77701423-0127BioMed CentralLondon pmcid: 7023813626 doi: 10.1186/s12929-020-0626-6 : Review Better" exact="influenza" post="vaccines: an industry perspective ChenJuine-Ruey1LiuYo-Min23TsengYung-Chieh2http://orcid.org/0000-0002-4741-2307MaChecma@gate.sinica.edu.tw2[1], [2], grid.28665.3f0000 0001 2287"/>
 <result pre="stated. Abstract Vaccination is the most effective measure at preventing" exact="influenza" post="virus infections. However, current seasonal influenza vaccines are only"/>
 <result pre="effective measure at preventing influenza virus infections. However, current seasonal" exact="influenza" post="vaccines are only protective against closely matched circulating strains."/>
 <result pre="resulting in mismatches and low vaccine effectiveness. Fortunately, many next-generation" exact="influenza" post="vaccines are currently in development, utilizing an array of"/>
 <result pre="of current vaccines, recent advances that have been made in" exact="influenza" post="vaccine research, and highlights potential challenges that are yet"/>
 <result pre="emphasis is put on the potential role of glycoengineering in" exact="influenza" post="vaccine development, and the advantages of removing the glycan"/>
 <result pre="development, and the advantages of removing the glycan shield on" exact="influenza" post="surface antigens to increase vaccine immunogenicity. The potential for"/>
 <result pre="vaccine immunogenicity. The potential for future development of these novel" exact="influenza" post="vaccine candidates is discussed from an industry perspective. Keywords"/>
 <result pre="Funding Academic Sinica Genomics Research Center Summit ProjectAS-SUMMIT-108MaChe Background Seasonal" exact="influenza" post="outbreaks cause 3 to 5 million cases of severe"/>
 <result pre="6~8 segments of negative-sense single-stranded RNA, including four genera of" exact="influenza" post="virus: A, B, C and D [3]. Influenza A"/>
 <result pre="the main cause of annual flu outbreaks in humans, with" exact="influenza" post="A further classified into subtypes based on their surface"/>
 <result pre="subtypes that co-circulate in the human population. Since the 1970s" exact="influenza" post="B has diverged into two lineages based on antigenicity,"/>
 <result pre="[4]. In contrast to the severity and epidemic potential of" exact="influenza" post="A and B, influenza C infections induce only mild"/>
 <result pre="the severity and epidemic potential of influenza A and B," exact="influenza" post="C infections induce only mild flu symptoms in children,"/>
 <result pre="C infections induce only mild flu symptoms in children, while" exact="influenza" post="D is not known to infect humans [5]. Recurrent"/>
 <result pre="influenza D is not known to infect humans [5]. Recurrent" exact="influenza" post="epidemics with pre-existing immunity occurs because the influenza virus"/>
 <result pre="[5]. Recurrent influenza epidemics with pre-existing immunity occurs because the" exact="influenza" post="virus employs two mechanisms to escape recognition: antigenic drift"/>
 <result pre="drift is the gradual accumulation of point mutations on the" exact="influenza" post="virus’ surface glycoproteins HA and NA, driven by high"/>
 <result pre="antigenicity [7, 8]. Antigenic shift have historically been associated with" exact="influenza" post="pandemics, the most recent example being the 2009 swine-origin"/>
 <result pre="existing strains with new variants [10, 11]. Unfortunately, current seasonal" exact="influenza" post="vaccines are strain-specific and have a very narrow range"/>
 <result pre="System (GISRS), which gathers year-round data from hundreds of national" exact="influenza" post="centers around the world and issue vaccine formulation recommendations"/>
 <result pre="current seasonal flu vaccine is facing, and how a universal" exact="influenza" post="vaccine approach through carbohydrate design to elicit broadly neutralizing"/>
 <result pre="carbohydrate design to elicit broadly neutralizing antibodies (bnAbs) targeting the" exact="influenza" post="HA glycoprotein can potentially play a role in the"/>
 <result pre="glycoprotein can potentially play a role in the future of" exact="influenza" post="prevention. Despite the first influenza vaccine being commercially available"/>
 <result pre="role in the future of influenza prevention. Despite the first" exact="influenza" post="vaccine being commercially available as early as 1945, influenza"/>
 <result pre="first influenza vaccine being commercially available as early as 1945," exact="influenza" post="outbreaks continue to be a major public health concern"/>
 <result pre="pharmaceutical industry to work together on improving the efficacy of" exact="influenza" post="vaccines. Limitations and drawbacks of current influenza vaccines Traditional"/>
 <result pre="the efficacy of influenza vaccines. Limitations and drawbacks of current" exact="influenza" post="vaccines Traditional trivalent influenza vaccines include two inactivated influenza"/>
 <result pre="vaccines. Limitations and drawbacks of current influenza vaccines Traditional trivalent" exact="influenza" post="vaccines include two inactivated influenza A strains (H1N1 and"/>
 <result pre="current influenza vaccines Traditional trivalent influenza vaccines include two inactivated" exact="influenza" post="A strains (H1N1 and H3N2) and one influenza B"/>
 <result pre="two inactivated influenza A strains (H1N1 and H3N2) and one" exact="influenza" post="B strain, but this has recently been overtaken by"/>
 <result pre="B strain, but this has recently been overtaken by quadrivalent" exact="influenza" post="vaccine comprised of H1N1, H3N2 and both influenza B"/>
 <result pre="by quadrivalent influenza vaccine comprised of H1N1, H3N2 and both" exact="influenza" post="B lineages that offers a more complete coverage [18]."/>
 <result pre="[18]. Commercially available vaccine options include egg- or cell-based inactivated" exact="influenza" post="vaccine (IIV), a live attenuated influenza vaccine (LAIV), and"/>
 <result pre="egg- or cell-based inactivated influenza vaccine (IIV), a live attenuated" exact="influenza" post="vaccine (LAIV), and a recombinant HA vaccine produced in"/>
 <result pre="recombinant HA vaccine produced in insect cells [16]. Egg-based inactivated" exact="influenza" post="vaccines The production of egg-based influenza vaccines has remained"/>
 <result pre="cells [16]. Egg-based inactivated influenza vaccines The production of egg-based" exact="influenza" post="vaccines has remained virtually unchanged since the advent of"/>
 <result pre="directly affect vaccine supply. This lengthy interval also gives circulating" exact="influenza" post="viruses time to mutate, as it did during the"/>
 <result pre="recommended vaccine strain ineffective [8]. Fig. 1 Timeline of current" exact="influenza" post="vaccine production methods. Schematic overview of egg-based, cell-based and"/>
 <result pre="vaccine production methods. Schematic overview of egg-based, cell-based and protein-based" exact="influenza" post="vaccine production. Vaccine strains that match circulating influenza viruses"/>
 <result pre="and protein-based influenza vaccine production. Vaccine strains that match circulating" exact="influenza" post="viruses for the upcoming flu season are selected by"/>
 <result pre="primary target for neutralizing antibodies, is the main facilitator of" exact="influenza" post="virus entry by binding to sialic acids on the"/>
 <result pre="sialic acids on the surface of the host cells. Human" exact="influenza" post="HA preferentially bind to α-2,6 linked sialic acids commonly"/>
 <result pre="increases in demand, such as during a pandemic. Live attenuated" exact="influenza" post="vaccines LAIV is generated by combining the HA and"/>
 <result pre="ability in the human upper respiratory tract. As the entire" exact="influenza" post="replication cycle is utilized at the site of infection,"/>
 <result pre="scalability as cell-based IIV, but also eliminates the reliance on" exact="influenza" post="virus replication for vaccine production and the time-consuming process"/>
 <result pre="However, the comparatively high cost of these alternatives to egg-based" exact="influenza" post="vaccines have prevented them from taking a bigger share"/>
 <result pre="have prevented them from taking a bigger share of the" exact="influenza" post="vaccine market. According to the US Centers for Disease"/>
 <result pre="According to the US Centers for Disease Control (CDC) adult" exact="influenza" post="vaccine contract pricing for 2019–2020, the cost of the"/>
 <result pre="more support from governments around the world is needed. Next-generation" exact="influenza" post="vaccines Various next-generation influenza vaccines under development aims to"/>
 <result pre="around the world is needed. Next-generation influenza vaccines Various next-generation" exact="influenza" post="vaccines under development aims to broaden or lengthen the"/>
 <result pre="&quot;universal�? pan-influenza vaccine that can elicit lifelong immunity against all" exact="influenza" post="A and B viruses [43]. From a public health"/>
 <result pre="A and B viruses [43]. From a public health perspective" exact="influenza" post="continues to be the only human disease that requires"/>
 <result pre="a detailed strategic plan for the development of a universal" exact="influenza" post="vaccine, highlighting knowledge gaps and research areas in pursuit"/>
 <result pre="In their outline, they established four criteria for a universal" exact="influenza" post="vaccine as: 75% effectiveness against symptomatic influenza infection, protection"/>
 <result pre="for a universal influenza vaccine as: 75% effectiveness against symptomatic" exact="influenza" post="infection, protection against both group I and group II"/>
 <result pre="influenza infection, protection against both group I and group II" exact="influenza" post="viruses, durable protection that last at least 1 year, and"/>
 <result pre="or head-stem chimera I bnAbs (no HAI) and ADCC; intranasal" exact="influenza" post="challenge [48–51] Academia Sinica and OPKO Monoglycosylated HA as"/>
 <result pre="PepTcell.Ltd FLU-V II Cross-reactive T-cell responses, and mucosal immunity; intranasal" exact="influenza" post="challenge [59–63] Live attenuated virus vaccine CodageniX CodaVax Live-attenuated"/>
 <result pre="I/II Additional antigens, T cell responses, and mucosal immunity; intranasal" exact="influenza" post="challenge [64–66] FluGen M2SR I/II T cell responses, and"/>
 <result pre="FluGen M2SR I/II T cell responses, and mucosal immunity; intranasal" exact="influenza" post="challenge [67, 68] DNA based vaccine Inovio RNA, DNA,"/>
 <result pre="Acambis/Sanofi Pasteur M2 ectodomain I/II bnAbs; ADCC (no NT); intranasal" exact="influenza" post="challenge [73, 74] Altering glycan composition on recombinant HA"/>
 <result pre="HA and split virus vaccines Historically, a crucial strategy of" exact="influenza" post="virus’ escape from pre-existing immunity is the addition of"/>
 <result pre="accrued and retained [78]. Overall, the continued circulation of an" exact="influenza" post="subtype in the human population corresponds to a steady"/>
 <result pre="could be a potential strategy to increase the breadth of" exact="influenza" post="vaccine protection [52, 81, 82]. However, previous attempts have"/>
 <result pre="attempts have shown complete de-glycosylation of all carbohydrate moieties on" exact="influenza" post="HA by either prokaryotic production [52], tunicamycin treatment [83]"/>
 <result pre="53]. Fig. 2 The production and immune response of monoglycosylated" exact="influenza" post="vaccine. The production of monoglycosylated split virus vaccine adds"/>
 <result pre="speed, flexibility and safety, egg-based production remains the mainstay of" exact="influenza" post="vaccine manufacture today. Devising a simple method to apply"/>
 <result pre="I inhibitor, can be injected into embryonated eggs to convert" exact="influenza" post="virus membrane glycoproteins to a uniformly high mannose composition."/>
 <result pre="steps [54]. Like the recombinant HAmg before, monoglycosylated split inactivated" exact="influenza" post="vaccines produced by kifunensine and endoglycosidase H treatment were"/>
 <result pre="procedure produces antigens that are virtually identical to the current" exact="influenza" post="vaccine, and would presumably offer a similar safety profile."/>
 <result pre="profile. Recombinant HA vaccines An adjuvanted recombinant HA trivalent nanoparticle" exact="influenza" post="vaccine (tNIV) has been developed by Novavax using the"/>
 <result pre="[48]. In a preclinical study, ferrets sequentially immunized with heterologous" exact="influenza" post="strains including live attenuated influenza vaccine (LAIV) bearing an"/>
 <result pre="ferrets sequentially immunized with heterologous influenza strains including live attenuated" exact="influenza" post="vaccine (LAIV) bearing an H8 head domain and an"/>
 <result pre="the M-001 vaccine induced both cellular and humoral immunity to" exact="influenza" post="A and B strains as a standalone vaccine [58],"/>
 <result pre="by SEEK (PepTcell) based on in silico multiple alignment of" exact="influenza" post="sequences and prediction of possible T-cell epitopes. Six consensus"/>
 <result pre="and prediction of possible T-cell epitopes. Six consensus sequences from" exact="influenza" post="NP, M1 and matrix 2 (M2) proteins were identified"/>
 <result pre="cells from immunized subjects exhibited cross reactive immunity against different" exact="influenza" post="viruses [62, 63]. Live attenuated influenza vaccines CodaVax is"/>
 <result pre="reactive immunity against different influenza viruses [62, 63]. Live attenuated" exact="influenza" post="vaccines CodaVax is an LAIV being developed by Codagenix"/>
 <result pre="advantage of inherent human codon pair bias to reconstruct the" exact="influenza" post="viral genome with synonymous but sub-optimal codons. This results"/>
 <result pre="of HA they have generated four &quot;micro-consensus�? sequences within an" exact="influenza" post="subtype, which were then cloned onto expression vectors and"/>
 <result pre="against lethal challenges. M2 conserved domain vaccine ACAM-FLU-A is an" exact="influenza" post="M2 ectodomain vaccine developed by Acambis (now Sanofi Pasteur)."/>
 <result pre="nucleotides with M1, the M2 ectodomain is highly conserved in" exact="influenza" post="A viruses, but poorly immunogenic [74]. ACAM-FLU-A utilizes the"/>
 <result pre="other antigens or adjuvants might be necessary. Challenges for universal" exact="influenza" post="vaccine development The need for accurate surrogate markers of"/>
 <result pre="of VE for clinical study and licensing approval Precisely characterizing" exact="influenza" post="immunity and correlates of immune protection is one of"/>
 <result pre="for improvement outlined in NIAID’s strategic plan for a universal" exact="influenza" post="vaccine [87]. Serological assays such as hemagglutination inhibition (HAI)"/>
 <result pre="by regulatory agencies as a correlate of protection for inactivated" exact="influenza" post="vaccine licensure. European Medicines Agency’s (EMA) Committee for Human"/>
 <result pre="for Human Medicinal Products (CHMP) criteria indicates that for seasonal" exact="influenza" post="vaccine approval one of three conditions must be met:"/>
 <result pre="system [90]. While this method measures all serum antibodies against" exact="influenza" post="surface antigens, it still does not recognize local mucosal"/>
 <result pre="to be taken into account for regulatory approval of next-generation" exact="influenza" post="vaccines [87, 88], though challenges in standardization of assays"/>
 <result pre="all aspects of our immune system are needed to control" exact="influenza" post="outbreaks. Eligibility for vulnerable groups Elderly people often have"/>
 <result pre="vulnerable groups Elderly people often have more serious complications from" exact="influenza" post="infections and a less robust immune response to vaccination"/>
 <result pre="response from specific populations that are at higher risk for" exact="influenza" post="complications. Long-term protection With traditional seasonal flu vaccine human"/>
 <result pre="wanes in 6–8 months of time, enough to last through the" exact="influenza" post="season [96, 97]. But if a universal vaccine were"/>
 <result pre="the four criteria set by the NIAID for a universal" exact="influenza" post="vaccine [87], but how to achieve that goal is"/>
 <result pre="all likely have to be considered. Conclusions The evolution of" exact="influenza" post="vaccine development has shown a trend of cell-based vaccines"/>
 <result pre="of next-generation vaccines currently under development, WHO expects a universal" exact="influenza" post="A vaccine to be in advanced clinical trials as"/>
 <result pre="shown to elicit cross-neutralizing antibodies against antigenically diverse strains of" exact="influenza" post="viruses within a subtype [52, 53], and thus hypothetically"/>
 <result pre="hypothetically a trivalent or tetravalent monoglycosylated vaccine containing the three" exact="influenza" post="subtypes (H1, H3, and influenza B) circulating in the"/>
 <result pre="monoglycosylated vaccine containing the three influenza subtypes (H1, H3, and" exact="influenza" post="B) circulating in the human population would be, for"/>
 <result pre="immune recognition Due to the rapid mutation rate of the" exact="influenza" post="virus, using only a single conserved epitope as the"/>
 <result pre="imposes a higher evolutionary barrier for escape mutant generation. Another" exact="influenza" post="glycoprotein that could potentially benefit from the monoglycosylation process"/>
 <result pre="infants &amp;lt; 6 months by maternal vaccination. Even though recent advances in" exact="influenza" post="vaccine manufacture such as cell-based and recombinant HA have"/>
 <result pre="production timeline, using conventional strain-specific vaccines against a rapidly evolving" exact="influenza" post="virus assures we are always playing catch-up. As our"/>
 <result pre="assures we are always playing catch-up. As our understanding of" exact="influenza" post="pathogenesis and immune response continues to grow, developing a"/>
 <result pre="B core IIV Inactivated Influenza Vaccine IIV3-HD high-dose inactivated trivalent" exact="influenza" post="vaccine LAIV Live attenuated influenza vaccine M1 Matrix 1"/>
 <result pre="Vaccine IIV3-HD high-dose inactivated trivalent influenza vaccine LAIV Live attenuated" exact="influenza" post="vaccine M1 Matrix 1 protein M2 Matrix 2 protein"/>
 <result pre="RNA-dependent RNA polymerase SRH Single Radial Hemolysis tNIV trivalent nanoparticle" exact="influenza" post="vaccine VE Vaccine Effectiveness WHO World Health Organization Publisher’s"/>
 <result pre="for publication Not applicable. Competing interests Patent applications of monoglycosylated" exact="influenza" post="vaccines have been submitted by Academia Sinica with C.M.,"/>
 <result pre="is in co-development with OPKO Health, Inc. on the monoglycosylated" exact="influenza" post="vaccine technology licensed by Academia Sinica. References References 1.collab:"/>
 <result pre="Med200410S8210.1038/nm114115577936 4.collab: WT RPAHarmonMWRotaJSKendalAPNeromeKCocirculation of two distinct evolutionary lineages of" exact="influenza" post="type B virus since 1983Virology19901751596810.1016/0042-6822(90)90186-U2309452 5.HauseBMCollinEALiuRHuangBShengZLuWet al.Characterization of a"/>
 <result pre="type B virus since 1983Virology19901751596810.1016/0042-6822(90)90186-U2309452 5.HauseBMCollinEALiuRHuangBShengZLuWet al.Characterization of a novel" exact="influenza" post="virus in cattle and swine: proposal for a new"/>
 <result pre="Orthomyxoviridae familyMBio201452e00031e0001410.1128/mBio.00031-1424595369 6.ParvinJDMosconaAPanWTLeiderJMPalesePMeasurement of the mutation rates of animal viruses:" exact="influenza" post="a virus and poliovirus type 1J Virol198659237738310.1128/JVI.59.2.377-383.19863016304 7.WebsterRGLWAirGMSchildGCMolecular mechanisms"/>
 <result pre="and poliovirus type 1J Virol198659237738310.1128/JVI.59.2.377-383.19863016304 7.WebsterRGLWAirGMSchildGCMolecular mechanisms of variation in" exact="influenza" post="virusesNature1982296585311512110.1038/296115a06174870 8.ChambersBSParkhouseKRossTMAlbyKHensleySEIdentification of Hemagglutinin residues responsible for H3N2 antigenic"/>
 <result pre="Hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015" exact="influenza" post="seasonCell Rep20151211610.1016/j.celrep.2015.06.00526119736 9.GartenRJDavisCTRussellCAShuBLindstromSBalishAet al.Antigenic and genetic characteristics of swine-origin"/>
 <result pre="Rep20151211610.1016/j.celrep.2015.06.00526119736 9.GartenRJDavisCTRussellCAShuBLindstromSBalishAet al.Antigenic and genetic characteristics of swine-origin 2009 a(H1N1)" exact="influenza" post="viruses circulating in humansScience2009325593719720110.1126/science.117622519465683 10.FergusonNMGalvaniAPBushRMEcological and immunological determinants of"/>
 <result pre="influenza viruses circulating in humansScience2009325593719720110.1126/science.117622519465683 10.FergusonNMGalvaniAPBushRMEcological and immunological determinants of" exact="influenza" post="evolutionNature200342242810.1038/nature0150912660783 11.BushRMBenderCASubbaraoKCoxNJFitchWMPredicting the evolution of human influenza aScience19992865446192110.1126/science.286.5446.192110583948 12.WHO."/>
 <result pre="immunological determinants of influenza evolutionNature200342242810.1038/nature0150912660783 11.BushRMBenderCASubbaraoKCoxNJFitchWMPredicting the evolution of human" exact="influenza" post="aScience19992865446192110.1126/science.286.5446.192110583948 12.WHO. Global Influenza Surveillance and Response System (GISRS)"/>
 <result pre="Aust19731333810.5694/j.1326-5377.1973.tb111174.x4717617 14.collab: CDCKey Facts About Influenza (Flu)2019 15.GoodwinKViboudCSimonsenLAntibody response to" exact="influenza" post="vaccination in the elderly: a quantitative reviewVaccine20062481159116910.1016/j.vaccine.2005.08.10516213065 16.GrohskopfLASokolowLZBroderKRWalterEBFryAMJerniganDBPrevention and"/>
 <result pre="the elderly: a quantitative reviewVaccine20062481159116910.1016/j.vaccine.2005.08.10516213065 16.GrohskopfLASokolowLZBroderKRWalterEBFryAMJerniganDBPrevention and control of seasonal" exact="influenza" post="with vaccines: recommendations of the advisory committee on immunization"/>
 <result pre="recommendations of the advisory committee on immunization practices-United States, 2018-19" exact="influenza" post="seasonMMWR Recomm Rep201867312010.15585/mmwr.rr6703a130141464 17.OhmitSEVictorJCRotthoffJRTeichERTrusconRKBaumLLet al.Prevention of antigenically drifted influenza"/>
 <result pre="2018-19 influenza seasonMMWR Recomm Rep201867312010.15585/mmwr.rr6703a130141464 17.OhmitSEVictorJCRotthoffJRTeichERTrusconRKBaumLLet al.Prevention of antigenically drifted" exact="influenza" post="by inactivated and live attenuated vaccinesN Engl J Med2006355242513252210.1056/NEJMoa06185017167134"/>
 <result pre="inactivated and live attenuated vaccinesN Engl J Med2006355242513252210.1056/NEJMoa06185017167134 18.TisaVBarberisIFaccioVPaganinoCTrucchiCMartiniMet al.Quadrivalent" exact="influenza" post="vaccine: a new opportunity to reduce the influenza burdenJ"/>
 <result pre="18.TisaVBarberisIFaccioVPaganinoCTrucchiCMartiniMet al.Quadrivalent influenza vaccine: a new opportunity to reduce the" exact="influenza" post="burdenJ Preventive Med hygiene2016571E28E33 19.Pandey S, Manjrekar S, Sumant"/>
 <result pre="https://www.alliedmarketresearch.com/influenza-vaccines-market 20.McLeanKAGoldinSNanneiCSparrowETorelliGThe 2015 global production capacity of seasonal and pandemic" exact="influenza" post="vaccineVaccine201634455410541310.1016/j.vaccine.2016.08.01927531411 21.WHO. Addendum to the recommended composition of influenza"/>
 <result pre="pandemic influenza vaccineVaccine201634455410541310.1016/j.vaccine.2016.08.01927531411 21.WHO. Addendum to the recommended composition of" exact="influenza" post="virus vaccines for use in the 2019–2020 northern hemisphere"/>
 <result pre="influenza virus vaccines for use in the 2019–2020 northern hemisphere" exact="influenza" post="season 2019. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/201902_recommendation_addendum.pdf?ua=1. [cited 2019 11/14]. 22.AbelinAColegateTGardnerSHehmeNPalacheALessons"/>
 <result pre="2019. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/201902_recommendation_addendum.pdf?ua=1. [cited 2019 11/14]. 22.AbelinAColegateTGardnerSHehmeNPalacheALessons from pandemic" exact="influenza" post="a(H1N1): the research-based vaccine industry's perspectiveVaccine20112961135113810.1016/j.vaccine.2010.11.04221115061 23.SkowronskiDMJanjuaNZDe SerresGSabaiducSEshaghiADickinsonJAet al.Low"/>
 <result pre="a(H1N1): the research-based vaccine industry's perspectiveVaccine20112961135113810.1016/j.vaccine.2010.11.04221115061 23.SkowronskiDMJanjuaNZDe SerresGSabaiducSEshaghiADickinsonJAet al.Low 2012–13" exact="influenza" post="vaccine effectiveness associated with mutation in the egg-adapted H3N2"/>
 <result pre="antigenic drift in circulating virusesPLoS One201493e9215310.1371/journal.pone.009215324667168 24.ZostSJParkhouseKGuminaMEKimKDiaz PerezSWilsonPCet al.Contemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
 <result pre="Natl Acad Sci2017114471257810.1073/pnas.171237711429109276 25.WidjajaLIlyushinaNWebsterRGWebbyRJMolecular changes associated with adaptation of human" exact="influenza" post="a virus in embryonated chicken eggsVirol2006350113714510.1016/j.virol.2006.02.020 26.NichollsJMChanRWYRussellRJAirGMPeirisJSMEvolving complexities of"/>
 <result pre="influenza a virus in embryonated chicken eggsVirol2006350113714510.1016/j.virol.2006.02.020 26.NichollsJMChanRWYRussellRJAirGMPeirisJSMEvolving complexities of" exact="influenza" post="virus and its receptorsTrends Microbiol200816414915710.1016/j.tim.2008.01.00818375125 27.ImaiMKawaokaYThe role of receptor"/>
 <result pre="27.ImaiMKawaokaYThe role of receptor binding specificity in interspecies transmission of" exact="influenza" post="virusesCurr Opinion Virol20122216016710.1016/j.coviro.2012.03.003 28.ItoTSuzukiYTakadaAKawamotoAOtsukiKMasudaHet al.Differences in sialic acid-galactose linkages"/>
 <result pre="linkages in the chicken egg amnion and allantois influence human" exact="influenza" post="virus receptor specificity and variant selectionJ Virol19977143357336210.1128/JVI.71.4.3357-3362.19979060710 29.HoftDFBabusisEWorkuSSpencerCTLottenbachKTruscottSMet al.Live"/>
 <result pre="receptor specificity and variant selectionJ Virol19977143357336210.1128/JVI.71.4.3357-3362.19979060710 29.HoftDFBabusisEWorkuSSpencerCTLottenbachKTruscottSMet al.Live and inactivated" exact="influenza" post="vaccines induce similar humoral responses, but only live vaccines"/>
 <result pre="T-cell responses in young childrenJ Infect Dis2011204684585310.1093/infdis/jir43621846636 30.MohnKG-IBrokstadKAPathiranaRDBredholtGJul-LarsenÅTrieuMCet al.Live attenuated" exact="influenza" post="vaccine in children induces B-cell responses in tonsilsJ Infect"/>
 <result pre="tonsilsJ Infect Dis2016214572273110.1093/infdis/jiw23027247344 31.GaglaniMPruszynskiJMurthyKClipperLRobertsonAReisMet al.Influenza vaccine effectiveness against 2009 pandemic" exact="influenza" post="a(H1N1) virus differed by vaccine type during 2013-2014 in"/>
 <result pre="type during 2013-2014 in the United StatesJ Infect Dis2016213101546155610.1093/infdis/jiv57726743842 32.TamTWSIntranasal" exact="influenza" post="vaccine: why does Canada have different recommendations from the"/>
 <result pre="its use?Paediatr Child Health2018231313410.1093/pch/pxx19529479277 33.SinganayagamAZambonMLalvaniABarclayWUrgent challenges in implementing live attenuated" exact="influenza" post="vaccineLancet Infect Dis2018181e25e3210.1016/S1473-3099(17)30360-228780285 34.GrohskopfLASokolowLZFryAMWalterEBJerniganDBUpdate: ACIP recommendations for the use"/>
 <result pre="34.GrohskopfLASokolowLZFryAMWalterEBJerniganDBUpdate: ACIP recommendations for the use of quadrivalent live attenuated" exact="influenza" post="vaccine (LAIV4)—United States, 2018–19 influenza seasonMorb Mortal Wkly Rep2018672264310.15585/mmwr.mm6722a5"/>
 <result pre="use of quadrivalent live attenuated influenza vaccine (LAIV4)—United States, 2018–19" exact="influenza" post="seasonMorb Mortal Wkly Rep2018672264310.15585/mmwr.mm6722a5 35.collab: Immunization NACoAn Advisory Committee"/>
 <result pre="efficacy, and immunogenicity of Flublok in the prevention of seasonal" exact="influenza" post="in adultsTherapeutic Advances Vaccin2015349710810.1177/2051013615595595 38.IzurietaHSChillarigeYKelmanJWeiYLuYXuWet al.Relative effectiveness of cell-cultured"/>
 <result pre="adultsTherapeutic Advances Vaccin2015349710810.1177/2051013615595595 38.IzurietaHSChillarigeYKelmanJWeiYLuYXuWet al.Relative effectiveness of cell-cultured and egg-based" exact="influenza" post="vaccines among elderly persons in the United States, 2017-2018J"/>
 <result pre="in the United States, 2017-2018J Infect Dis201922081255126410.1093/infdis/jiy71630561688 39.CoxMMJHashimotoYA fast track" exact="influenza" post="virus vaccine produced in insect cellsJ Invertebr Pathol2011107S31S4110.1016/j.jip.2011.05.00321784229 40.DunkleLMIziksonRPatriarcaPGoldenthalKLMuseDCallahanJet"/>
 <result pre="produced in insect cellsJ Invertebr Pathol2011107S31S4110.1016/j.jip.2011.05.00321784229 40.DunkleLMIziksonRPatriarcaPGoldenthalKLMuseDCallahanJet al.Efficacy of recombinant" exact="influenza" post="vaccine in adults 50 years of age or olderN"/>
 <result pre="https://www.whitehouse.gov/briefings-statements/statement-press-secretary-executive-order-modernizing-influenza-vaccines-u-s-promote-national-security-public-health/. Cited 2020 Feb 3 43.PaulesCIMarstonHDEisingerRWBaltimoreDFauciASThe pathway to a universal" exact="influenza" post="vaccineImmunity201747459960310.1016/j.immuni.2017.09.00729045889 44.SahPAlfaro-MurilloJAFitzpatrickMCNeuzilKMMeyersLASingerBHet al.Future epidemiological and economic impacts of universal"/>
 <result pre="influenza vaccineImmunity201747459960310.1016/j.immuni.2017.09.00729045889 44.SahPAlfaro-MurilloJAFitzpatrickMCNeuzilKMMeyersLASingerBHet al.Future epidemiological and economic impacts of universal" exact="influenza" post="vaccinesProc Natl Acad Sci201911641207862079210.1073/pnas.190961311631548402 45.SmithGLiuYFlyerDMassareMJZhouBPatelNet al.Novel hemagglutinin nanoparticle influenza"/>
 <result pre="universal influenza vaccinesProc Natl Acad Sci201911641207862079210.1073/pnas.190961311631548402 45.SmithGLiuYFlyerDMassareMJZhouBPatelNet al.Novel hemagglutinin nanoparticle" exact="influenza" post="vaccine with matrix-M adjuvant induces hemagglutination inhibition, neutralizing, and"/>
 <result pre="against homologous and drifted a(H3N2) subtypesVaccine201735405366537210.1016/j.vaccine.2017.08.02128844407 46.ShindeVFriesLWuYAgrawalSChoIThomasDNet al.Improved titers against" exact="influenza" post="drift variants with a nanoparticle vaccineN Engl J Med2018378242346234810.1056/NEJMc180355429897849"/>
 <result pre="in future vaccines relies on formulationExpert Rev Vaccines201110440140310.1586/erv.11.2521506635 48.KrammerFPicaNHaiRMargineIPalesePChimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodiesJ Virol201387126542655010.1128/JVI.00641-1323576508"/>
 <result pre="constructs elicit broadly protective stalk-specific antibodiesJ Virol201387126542655010.1128/JVI.00641-1323576508 49.NachbagauerRLiuWCChoiAWohlboldTJAtlasTRajendranMet al.A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
 <result pre="in preclinical ferret studiesNPJ Vaccines201722610.1038/s41541-017-0026-429263881 50.KrammerFMargineIHaiRFloodAHirshATsvetnitskyVet al.H3 stalk-based chimeric hemagglutinin" exact="influenza" post="virus constructs protect mice from H7N9 challengeJ Virol20148842340234310.1128/JVI.03183-1324307585 51.KrammerFPalesePSteelJAdvances"/>
 <result pre="constructs protect mice from H7N9 challengeJ Virol20148842340234310.1128/JVI.03183-1324307585 51.KrammerFPalesePSteelJAdvances in universal" exact="influenza" post="virus vaccine design and antibody mediated therapies based on"/>
 <result pre="regions of the hemagglutininCurr Top Microbiol Immunol201538630132125007847 52.WangCCChenJRTsengYCHsuCHHungYFChenSWet al.Glycans on" exact="influenza" post="hemagglutinin affect receptor binding and immune responseProc Natl Acad"/>
 <result pre="A200910643181371814210.1073/pnas.090969610619822741 53.ChenJRYuYHTsengYCChiangWLChiangMFKoYAet al.Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against" exact="influenza" post="virus infectionsProc Natl Acad Sci U S A201411172476248110.1073/pnas.132395411124469815 54.TsengYCWuCYLiuMLChenTHChiangWLYuYHet"/>
 <result pre="virus infectionsProc Natl Acad Sci U S A201411172476248110.1073/pnas.132395411124469815 54.TsengYCWuCYLiuMLChenTHChiangWLYuYHet al.Egg-based" exact="influenza" post="split virus vaccine with monoglycosylation induces cross-strain protection against"/>
 <result pre="influenza split virus vaccine with monoglycosylation induces cross-strain protection against" exact="influenza" post="virus infectionsProc Natl Acad Sci U S A2019116104200420510.1073/pnas.181919711630782805 55.AtsmonJCaracoYZiv-SeferSShaikevichDAbramovEVolokhovIet"/>
 <result pre="Sci U S A2019116104200420510.1073/pnas.181919711630782805 55.AtsmonJCaracoYZiv-SeferSShaikevichDAbramovEVolokhovIet al.Priming by a novel universal" exact="influenza" post="vaccine (Multimeric-001)-a gateway for improving immune response in the"/>
 <result pre="response in the elderly populationVaccine201432445816582310.1016/j.vaccine.2014.08.03125173483 56.GottliebTBen-YedidiaTEpitope-based approaches to a universal" exact="influenza" post="vaccineJ Autoimmun201454152010.1016/j.jaut.2014.07.00525172355 57.AtsmonJKate-IlovitzEShaikevichDSingerYVolokhovIHaimKYet al.Safety and immunogenicity of multimeric-001--a novel"/>
 <result pre="vaccineJ Autoimmun201454152010.1016/j.jaut.2014.07.00525172355 57.AtsmonJKate-IlovitzEShaikevichDSingerYVolokhovIHaimKYet al.Safety and immunogenicity of multimeric-001--a novel universal" exact="influenza" post="vaccineJ Clin Immunol201232359560310.1007/s10875-011-9632-522318394 58.van DoornELiuHBen-YedidiaTHassinSVisontaiINorleySet al.Evaluating the immunogenicity and"/>
 <result pre="DoornELiuHBen-YedidiaTHassinSVisontaiINorleySet al.Evaluating the immunogenicity and safety of a BiondVax-developed universal" exact="influenza" post="vaccine (Multimeric-001) either as a standalone vaccine or as"/>
 <result pre="as a standalone vaccine or as a primer to H5N1" exact="influenza" post="vaccine: phase IIb study protocolMedicine (Baltimore)20179611e633910.1097/MD.000000000000633928296763 59.StoloffGACaparros-WanderleyWSynthetic multi-epitope peptides"/>
 <result pre="multi-epitope peptides identified in silico induce protective immunity against multiple" exact="influenza" post="serotypesEur J Immunol20073792441244910.1002/eji.20073725417668898 60.PleguezuelosORobinsonSStoloffGACaparros-WanderleyWSynthetic influenza vaccine (FLU-v) stimulates cell"/>
 <result pre="induce protective immunity against multiple influenza serotypesEur J Immunol20073792441244910.1002/eji.20073725417668898 60.PleguezuelosORobinsonSStoloffGACaparros-WanderleyWSynthetic" exact="influenza" post="vaccine (FLU-v) stimulates cell mediated immunity in a double-blind,"/>
 <result pre="safety of different doses and formulations of a broad spectrum" exact="influenza" post="vaccine (FLU-v) developed by SEEK: study protocol for a"/>
 <result pre="placebo-controlled clinical phase IIb trialBMC Infect Dis201717124110.1186/s12879-017-2341-928376743 62.PleguezuelosORobinsonSFernandezAStoloffGAMannAGilbertAet al.A synthetic" exact="influenza" post="virus vaccine induces a cellular immune response that correlates"/>
 <result pre="lectins: selective inhibitors of viral entryAntivir Res2017142375410.1016/j.antiviral.2017.03.00728322922 64.MuellerSColemanJRPapamichailDWardCBNimnualAFutcherBet al.Live attenuated" exact="influenza" post="virus vaccines by computer-aided rational designNat Biotechnol201028772372610.1038/nbt.163620543832 65.YangCSkienaSFutcherBMuellerSWimmerEDeliberate reduction"/>
 <result pre="designNat Biotechnol201028772372610.1038/nbt.163620543832 65.YangCSkienaSFutcherBMuellerSWimmerEDeliberate reduction of hemagglutinin and neuraminidase expression of" exact="influenza" post="virus leads to an ultraprotective live vaccine in miceProc"/>
 <result pre="miceProc Natl Acad Sci U S A2013110239481948610.1073/pnas.130747311023690603 66.StauftCBYangCColemanJRBoltzDChinCKushnirAet al.Live-attenuated H1N1" exact="influenza" post="vaccine candidate displays potent efficacy in mice and ferretsPLoS"/>
 <result pre="and ferretsPLoS One20191410e022378410.1371/journal.pone.022378431609986 67.SarawarSHattaYWatanabeSDiasPNeumannGKawaokaYet al.M2SR, a novel live single replication" exact="influenza" post="virus vaccine, provides effective heterosubtypic protection in miceVaccine201634425090509810.1016/j.vaccine.2016.08.06127595896 68.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPNovel"/>
 <result pre="influenza virus vaccine, provides effective heterosubtypic protection in miceVaccine201634425090509810.1016/j.vaccine.2016.08.06127595896 68.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPNovel" exact="influenza" post="vaccine M2SR protects against drifted H1N1 and H3N2 influenza"/>
 <result pre="68.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPNovel influenza vaccine M2SR protects against drifted H1N1 and H3N2" exact="influenza" post="virus challenge in ferrets with pre-existing immunityVaccine201836335097510310.1016/j.vaccine.2018.06.05330007825 69.ElliottSTCKeatonAAChuJDReedCCGarmanBPatelAet al.A"/>
 <result pre="pre-existing immunityVaccine201836335097510310.1016/j.vaccine.2018.06.05330007825 69.ElliottSTCKeatonAAChuJDReedCCGarmanBPatelAet al.A synthetic micro-consensus DNA vaccine generates comprehensive" exact="influenza" post="a H3N2 immunity and protects mice against lethal challenge"/>
 <result pre="virusesHum Gene Ther20182991044105510.1089/hum.2018.10230062926 70.YanJMorrowMPChuJSRacineTReedCCKhanASet al.Broad cross-protective anti-hemagglutination responses elicited by" exact="influenza" post="microconsensus DNA vaccineVaccine201836223079308910.1016/j.vaccine.2017.09.08629100705 71.YanJVillarrealDORacineTChuJSWaltersJNMorrowMPet al.Protective immunity to H7N9 influenza"/>
 <result pre="by influenza microconsensus DNA vaccineVaccine201836223079308910.1016/j.vaccine.2017.09.08629100705 71.YanJVillarrealDORacineTChuJSWaltersJNMorrowMPet al.Protective immunity to H7N9" exact="influenza" post="viruses elicited by synthetic DNA vaccineVaccine201432242833284210.1016/j.vaccine.2014.02.03824631084 72.ChooAYBroderickKEKimJJSardesaiNYDNA-based influenza vaccines:"/>
 <result pre="to H7N9 influenza viruses elicited by synthetic DNA vaccineVaccine201432242833284210.1016/j.vaccine.2014.02.03824631084 72.ChooAYBroderickKEKimJJSardesaiNYDNA-based" exact="influenza" post="vaccines: evaluating their potential to provide universal protectionIDrugs2010131070771220878593 73.De"/>
 <result pre="evaluating their potential to provide universal protectionIDrugs2010131070771220878593 73.De FiletteMMartensWSmetASchotsaertMBirkettALondono-ArcilaPet al.Universal" exact="influenza" post="a M2e-HBc vaccine protects against disease even in the"/>
 <result pre="even in the presence of pre-existing anti-HBc antibodiesVaccine200826516503650710.1016/j.vaccine.2008.09.03818835315 74.DengLChoKJFiersWSaelensXM2e-based universal" exact="influenza" post="a vaccinesVaccines (Basel)20153110513610.3390/vaccines301010526344949 75.O'DonnellCDWrightAVogelLNWeiCJNabelGJSubbaraoKEffect of priming with H1N1 influenza"/>
 <result pre="universal influenza a vaccinesVaccines (Basel)20153110513610.3390/vaccines301010526344949 75.O'DonnellCDWrightAVogelLNWeiCJNabelGJSubbaraoKEffect of priming with H1N1" exact="influenza" post="viruses of variable antigenic distances on challenge with 2009"/>
 <result pre="virusJ Virol201286168625863310.1128/JVI.00147-1222674976 76.TateMDJobERDengYMGunalanVMaurer-StrohSReadingPCPlaying hide and seek: how glycosylation of the" exact="influenza" post="virus hemagglutinin can modulate the immune response to infectionViruses2014631294131610.3390/v603129424638204"/>
 <result pre="protein modulate the virulence and antigenic properties of the H1N1" exact="influenza" post="virusesSci Transl Med20135187187ra7010.1126/scitranslmed.30059963940933 78.KobayashiYSuzukiYEvidence for N-glycan shielding of antigenic"/>
 <result pre="for N-glycan shielding of antigenic sites during evolution of human" exact="influenza" post="a virus hemagglutininJ Virol20128673446345110.1128/JVI.06147-1122258255 79.WeiCJBoyingtonJCDaiKHouserKVPearceMBKongWPet al.Cross-neutralization of 1918 and"/>
 <result pre="a virus hemagglutininJ Virol20128673446345110.1128/JVI.06147-1122258255 79.WeiCJBoyingtonJCDaiKHouserKVPearceMBKongWPet al.Cross-neutralization of 1918 and 2009" exact="influenza" post="viruses: role of glycans in viral evolution and vaccine"/>
 <result pre="addition of oligosaccharides on the biological activities and antigenicity of" exact="influenza" post="a/H3N2 virus HemagglutininJ Virol200478189605961110.1128/JVI.78.18.9605-9611.200415331693 81.ChenJRMaCWongCHVaccine design of hemagglutinin glycoprotein"/>
 <result pre="the HIV-1-glycan shield on antibody elicitationCell Rep201719471973210.1016/j.celrep.2017.04.01328445724 83.HurtleySMBoleDGHoover-LittyHHeleniusACopelandCSInteractions of misfolded" exact="influenza" post="virus hemagglutinin with binding protein (BiP)J Cell Biol198910862117212610.1083/jcb.108.6.21172738090 84.RobertsPCGartenWKlenkHDRole"/>
 <result pre="84.RobertsPCGartenWKlenkHDRole of conserved glycosylation sites in maturation and transport of" exact="influenza" post="a virus hemagglutininJ Virol19936763048306010.1128/JVI.67.6.3048-3060.19938497042 85.LowellGHZivSBruzilSBabecoffRBen-YedidiaTBack to the future: immunization"/>
 <result pre="85.LowellGHZivSBruzilSBabecoffRBen-YedidiaTBack to the future: immunization with M-001 prior to trivalent" exact="influenza" post="vaccine in 2011/12 enhanced protective immune responses against 2014/15"/>
 <result pre="of Universal Influenza VaccinesJ Infect Dis2019219Supplement 1S68S7410.1093/infdis/jiz00330715367 87.ErbeldingEJPostDJStemmyEJRobertsPCAugustineADFergusonSet al.A universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
 <result pre="Dis2018218334735410.1093/infdis/jiy10329506129 88.WijnansLVoordouwBA review of the changes to the licensing of" exact="influenza" post="vaccines in EuropeInfluenza Other Respir Viruses20161012810.1111/irv.1235126439108 89.WeirJPGruberMFAn overview of"/>
 <result pre="EuropeInfluenza Other Respir Viruses20161012810.1111/irv.1235126439108 89.WeirJPGruberMFAn overview of the regulation of" exact="influenza" post="vaccines in the United StatesInfluenza Other Respir Viruses201610535436010.1111/irv.1238327426005 90.SchildGCPereiraMSChakravertyPSingle-radial-hemolysis:"/>
 <result pre="90.SchildGCPereiraMSChakravertyPSingle-radial-hemolysis: a new method for the assay of antibody to" exact="influenza" post="haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenzaBull"/>
 <result pre="Organ197552143501082381 91.GianchecchiETorelliAMontomoliEThe use of cell-mediated immunity for the evaluation of" exact="influenza" post="vaccines: an upcoming necessityHuman Vaccin Immunotherapeutics20191551021103010.1080/21645515.2019.1565269 92.OxfordJSOxfordJRClinical, scientific and"/>
 <result pre="upcoming necessityHuman Vaccin Immunotherapeutics20191551021103010.1080/21645515.2019.1565269 92.OxfordJSOxfordJRClinical, scientific and ethnographic studies of" exact="influenza" post="in quarantineExpert Rev Vaccin201211892993710.1586/erv.12.77 93.OxfordJSGelderCLambkinRWould you volunteer to be"/>
 <result pre="Vaccin201211892993710.1586/erv.12.77 93.OxfordJSGelderCLambkinRWould you volunteer to be quarantined and infected with" exact="influenza" post="virus?Expert Rev Anti-Infect Ther2005311210.1586/14787210.3.1.115757450 94.WilkinsonTMLiCKChuiCSHuangAKPerkinsMLiebnerJCet al.Preexisting influenza-specific CD4+ T"/>
 <result pre="al.Preexisting influenza-specific CD4+ T cells correlate with disease protection against" exact="influenza" post="challenge in humansNat Med201218227428010.1038/nm.261222286307 95.GovaertTMThijsCTMasurelNSprengerMJDinantGJKnottnerusJAThe efficacy of influenza vaccination"/>
 <result pre="protection against influenza challenge in humansNat Med201218227428010.1038/nm.261222286307 95.GovaertTMThijsCTMasurelNSprengerMJDinantGJKnottnerusJAThe efficacy of" exact="influenza" post="vaccination in elderly individuals. A randomized double-blind placebo-controlled trialJAMA1994272211661166510.1001/jama.1994.035202100450307966893"/>
 <result pre="individuals. A randomized double-blind placebo-controlled trialJAMA1994272211661166510.1001/jama.1994.035202100450307966893 96.PetrieJGOhmitSETrusconRJohnsonEBraunTMLevineMZet al.Modest waning of" exact="influenza" post="vaccine efficacy and antibody titers during the 2007-2008 influenza"/>
 <result pre="of influenza vaccine efficacy and antibody titers during the 2007-2008" exact="influenza" post="seasonJ Infect Dis201621481142114910.1093/infdis/jiw10527095420 97.FerdinandsJMFryAMReynoldsSPetrieJGFlanneryBJacksonMLet al.Intraseason waning of influenza vaccine"/>
 <result pre="the 2007-2008 influenza seasonJ Infect Dis201621481142114910.1093/infdis/jiw10527095420 97.FerdinandsJMFryAMReynoldsSPetrieJGFlanneryBJacksonMLet al.Intraseason waning of" exact="influenza" post="vaccine protection: evidence from the US influenza vaccine effectiveness"/>
 <result pre="al.Intraseason waning of influenza vaccine protection: evidence from the US" exact="influenza" post="vaccine effectiveness network, 2011–2012 through 2014–2015Clin Infect Dis201764554455028039340 98.collab:"/>
 <result pre="Dis201764554455028039340 98.collab: Organization WHWHO preferred product characteristics for next generation" exact="influenza" post="vaccines2017 99.ChaiNSwemLRReicheltMChen-HarrisHLuisEParkSet al.Two escape mechanisms of influenza a virus"/>
 <result pre="for next generation influenza vaccines2017 99.ChaiNSwemLRReicheltMChen-HarrisHLuisEParkSet al.Two escape mechanisms of" exact="influenza" post="a virus to a broadly neutralizing stalk-binding antibodyPLoS Pathog2016126e100570210.1371/journal.ppat.100570227351973"/>
 <result pre="affect viral escape from broad and narrow antibodies to H1" exact="influenza" post="hemagglutininNat Commun201891138610.1038/s41467-018-03665-329643370 101.MarcelinGSandbulteMRWebbyRJContribution of antibody production against neuraminidase to"/>
 <result pre="of antibody production against neuraminidase to the protection afforded by" exact="influenza" post="vaccinesRev Med Virol201222426727910.1002/rmv.171322438243"/>
</results>
